Sponsor: Apollo Therapeutics
Sponsor Study ID: AP10CP01
Study Title: A Phase 1/2 Study to Assess the Safety and Antitumor Activity of APL-5125 in Adults with Selected Advanced Solid Tumors
CTO #: 104054
NCT Number: NCT06399757
Phase: I/II
Protocol Type: Treatment
Age Group: Adults
Disease Sites: Colon, Rectum
Study Objectives: Evaluate the safety of APL-5125. Determine recommended phase 2 dose (RP2D) levels of APL-5125. Estimate the maximum tolerated dose (MTD) of APL-5125 in participants with selected advanced solid tumors.